Pharmacokinetic-pharmacodynamic relationships of acarbose

Clinical Pharmacokinetics

Volumn 30, Issue 2, 1996, Pages 94-106

  Salvatore, Teresa ^a,b   Giugliano, Dario ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE; GASTROINTESTINAL HORMONE; GLUCOSE; INSULIN; LIPID; MONOSACCHARIDE; OLIGOSACCHARIDE; SULFONYLUREA;

ATHEROSCLEROSIS; BINDING AFFINITY; BINDING SITE; CARBOHYDRATE ABSORPTION; CLINICAL TRIAL; COMPETITIVE INHIBITION; DIABETES MELLITUS; DIET; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONE RELEASE; HUMAN; HYPOGLYCEMIA; INCIDENCE; INGESTION; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE CELL; INTRAVENOUS DRUG ADMINISTRATION; LIPID BLOOD LEVEL; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TIME; WEIGHT GAIN;

EID: 0030066421     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199630020-00002     Document Type: Review

References (99)

1. Creutzfeldt W, Fölsch UR, editors. Delaying absorption as a therapeutic principle in metabolic diseases. Stuttgart: Georg Thieme Verlag, 1983
2. Puls W, Keup U. Influence of an α-amylase inhibitor (BAY D 7791) on blood glucose, serum insulin and NEFA in starch loading tests in rats, dogs and men. Diabetologia 1973; 9: 97-101
3. Truscheit E, Hillebrand I, Junge B, et al. Microbial α-glucosidase inhibitors: chemistry, biochemistry and therapeutic potential. Prog Clin Biochem Med 1988; 7: 17-99
4. Puls W, Keup U, Krause HP, et al. Glucosidase inhibition: a new approach to the treatment of diabetes, obesity and hyperlipoproteinaemia. Naturwissenschaften 1977; 64: 536-7
5. Bischoff H, Puls W, Krause HP, et al. Pharmacological properties of the novel glucosidase inhibitors BAY M 1099 (miglitol) and BAY O 1248. Diabetes Res Clin Pract 1985; Suppl 1: S53
6. Ikeda H, Odaka H, Matsuo T. Effect of a disaccharidase inhibitor, AO-128, on a high sucrose-diet-induced hyperglycemia in female Wistar fatty rats. Jpn Pharmacol Ther 1991; 19: 4451-6
7. Gray GM. Carbohydrate absorption and malabsorption. In: Johanson LR, Christensen J, Grossman MI, et al., editors. Physiology of the gastrointestinal tract. Vol. 2. New York: Raven, 1981: 1063-72
8. Fölsch UR, Lembcke B. Inhibition of intestinal alpha-glucosidase in the treatment of diabetes mellitus. Internist 1991; 32: 699-707
9. Newcomer AD, McGill DB. Distribution of disaccharidase activity in the small bowel of normal and lactase-deficient subjects. Gastroenterology 1966; 51: 481-8
10. Toeller M. Modulation of intestinal glucose absorption: postponement of glucose absorption by α-glucosidase inhibitors. In: Mogensen CE, Standl E, editors. Pharmacology of diabetes. Present practice and future perspectives. New York: W. De Gruyter, 1991; 93-112
11. Pütter J, Keup U, Krause HP, et al. Pharmacokinetics of acarbose. In: Creutzfeldt W, editor. Proceedings of the First International Symposium on Acarbose; 1981 Oct 8-10: Montreux. Amsterdam: Excerpta Medica, 1982; 38-48
12. Püttet J. Studies on the pharmacokinetics of acarbose in humans. In: Broodbeck U, editor. Enzyme inhibitors. Weinheim: Verlag Chemie, 1980; 139-51
13. 14C acarbose to rats and dogs. Arzneim Forsch 1989; 39 (II): 1261-7
14. 14C acarbose to rats, dogs and man. Arzneim Forsch 1989; 39 (II): 1254-60
15. Schmidt DD, Frommer W, Junge B, et al. α-Glucosidase inhibitors. New complex oligosaccharides of microbial origin. Naturwissenschaften 1977; 64: 535-6
16. Taylor RH, Barker HM, Bowey EA, et al. Regulation of the absorption of dietary carbohydrate in man by two new glycosidase inhibitors. Gut 1986; 27: 1471-8
17. Caspary WF, Graf SD. Inhibition of human intestinal α-glucosidehydrolases by a new complex oligosaccharide. Res Exp Med (Berl) 1979; 175: 1-6
18. Müller FO, Hillebrand I, Acarbose (BAY g 5421) kinetics in healthy volunteers. Acta Pharmacol Toxicol 1986; 59 (5 Suppl.): 303
19. Heiker FR, Boeshagen H, Junge B, et al. Studies designed to loca ise the essential structural unit of glycoside-hydrolase inhibitors of the acarbose type. In: Creutzfeldt W, editor. Proceedings of the First International Symposium on Acarbose; 198 Oct 8-10: Montreux. Amsterdam: Excerpta Medica, 1982: 137-41
20. Junge E, Boeshagen H, Stoltefuss J, et al. Derivatives of acarbose and their inhibitory effects on α-glucosidases. In: Brodbeck U, editor. Enzyme inhibitors. Weinheim: Verlag Chemie, 1980, 123-37
21. Schmidt DD, Frommer W, Junge B, et al. α-Glucosidase inhibitors of microbial origin. In: Creutzfeldt W, editor. Proceedings of the First International Symposium on Acarbose, 1981 Oct 8-10: Montreux. Amsterdam: Excerpta Medica, 1982, 5-15
22. Taylor RH, Jenkins DJA, Barker HM, et al. Effect of acarbose on the 24-hour blood glucose profile and pattern of carbohydrate absorption. Diabetes Care 1982; 5: 92-6
23. Lembcke B. Therapieprinzip Resorptionsverzögerung. Wirkprinzip α-Glukosidase-Inhibition. Berlin: Springer-Verlag, 1991
24. Müller L, Puls W. Pharmakologie der α-Glukosidase-Inhibitoren. In: Caspary WF, editor. Struktur and Funktion des Dünndarms. Amsterdam: Excerpta Medica, 1987: 288-308
25. Puls W, Keup U, Krause HP, et al. Pharmacology of α-glucosidase inhibitor. In: Creutzfeldt W, editor. Front Hormone Res 1980; 7: 235-47
26. Suehiro I, Otsuki M, Yamasaki T, et al. Effect of α-glucosidase inhibitor on human pancreatic and salivary amylase. Clin Chim Acta 1981; 117: 145-52
27. Puls W, Bischoff H. The pharmacological rationale of diabetes mellitus therapy with acarbose. In: Creutzfeldt W, editor. Acarbose for the treatment of diabetes mellitus. Proceedings of the 2nd International Symposium on Acarbose. Berlin: Springer-Verlag, 1988; 29-38
28. Caspary WF. Inhibitors influencing carbohydrate absorption. In: Creutzfeldt W, Lefebvre PJ, editors. Diabetes mellitus: pathophysiology and Therapy. Berlin: Springer-Verlag, 1989: 172-91
29. Toeller M. Dietary treatment and α-glucosidase inhibitors in NIDDM. Diabetes Nutr Metab 1990; 3 (1 Suppl.): 43-9
30. Toeller M. Inhibiteurs de 1'α-glucosidase. J Hôtel-Dieu Annu Diabetol 1991; 203-12
31. Müller L. Chemistry, biochemistry and therapeutic potential of microbial α-glucosidase inhibitors. In: Demain AL, Somkuti GA, Hunters-Cevera JC, et al. editors. Novel microbial products for medicine and agriculture. Amsterdam: Elsevier, 1989: 109-16
32. Hillebrand I, Boehme K, Frank U, et al. The effects of the α-glucosidase inhibitor BAY G 5421 (acarbose) on meal-stimulated elevations of circulating glucose, insulin and triglyceride levels in man. Res Exp Med 1979; 175: 81-6
33. Schrezenmeir J, Kasper H, Flasshoff HJ. The effect of acarbose on faecal composition. In: Creutzfeldt W, editor. Proceedings of the First International Symposium on Acarbose; 1981 Oct 8-10: Montreux. Amsterdam: Excerpta Medica, 1982, 225-31
34. Tuomilehto J. Acarbose monotherapy in the treatment of non-insulin-dependent diabetes mellitus: a review. In: Creutzfeldt W, editor. Acarbose for the treatment of diabetes mellitus. New York: Springer, 1988: 104-16
35. Hanefeld M, Fischer S, Schulze J, et al. Therapeutical potentials of acarbose as first-line drug in non-insulin-dependent diabetes insufficiently treated with diet alone. Diabetes Care 1991; 14: 732-7
36. Willms B. Stellenwert der Acarbose im Rahmen der aktuellen Diätempfehlungen für Diabeliker. Akt Endokr Stoffw 1991; 12: 1-10
37. Seiberling M, Toeller M, Baunack AR, et al. Beeinflußt der Kohlenhydrat-anteil der Mahlzeit die Insulin- und Blutglukose-antwort unter Acarbosegabe? Naunyn-Schmiedebergs Archiv Pharmacol 1989; 339; Abstract 301
38. Oerter E, Pfeffer H, Keller U, et al. Zum Stoffwechseleffekt won Diabetesdiäten mit unterschiedlichem Gehalt an Hohlenhydraten und Ballaststoffen. Der Einfluß von Acarbose. Akt Endokr Stoffw 1989; 10: 117
39. American Diabetes Association. Nutritional recommendations and principles for individuals with diabetes mellitus (1986 Position Statement). Diabetes Care 1987; 10: 126-32
40. Diabetes and Nutrition Study Group of The European Association for the Study of Diabetes. Nutritional recommendations for individuals with diabetes mellitus (Statement). Diabetes Nutr Metab 1988; 1: 145-9
41. Reaven GM, Lardinois CK, Greenfield MS, et al. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care 1990; 13 (3 Suppl.): 32-6
42. Scott RS, Knowles RL, Beaven DW. Treatment of poorly controlled non-insulin dependent diabetic patients with acarbose. Aust NZ J Med 1984; 14: 649-54
43. Hotta N, Kakuta H, Sano T, et al. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. Diabetic Med 1993; 10: 134-8
44. Göke B, Herrmann C, Göke R, et al. Intestinal effects of α-glucosidase inhibitors: absorption of nutrients and enterohormonal changes. Eur J Clin Invest 1994; 24 (3 Suppl.): 25-30
45. Ebert R, Creutzfeldt W, Brown JC, et al. Response of gastric inhibitory polypeptide (GIP) to test meal in chronic pancreatitis - relationship to endocrine and exocrine insufficiency. Diabetologia 1976; 12: 609-12
46. Ebert R, Creutzfeldt W. Decreased GIP secretion through impairment of absorption. Front Horm Res 1980; 7: 192-201
47. Fölsch UR, Lembcke B, Höpfner M, et al. The enteroinsular axis during treatment with glucosidase inhibitors. Front Horm Res 1987; 16: 197-205
48. Fukase N, Takahashi H, Igarashi M, et al. Differences in glucagon-like peptide 1 and GIP responses following sucrose ingestion. Diab Res Clin Pract 1992; 15: 187-95
49. Jenkins DJA, Taylor RH, Nineham R et al. Combined use of guar and acarbose in reduction of postprandial glycaemia. Lancet 1979; II: 924-7
50. Ross S, Hunt J, Josse R et al. Acarbose significantly improves glucose control in non-insulin-dependent diabetes mellitus subjects (NIDDM): results of the multi-centre Canadian trial [abstract]. Diabetes 1992; 41 (1 Suppl.): 193A
51. Toeller M. α-Glucosidase inhibitors in diabetes: efficacy in NIDDM subjects. Eur J Clin Invest 1994; 24 (3 Suppl.): 31-5
52. Innerfield RJ, Coniff RF. A multi-center, double-blind, placebo-controlled study of long-term efficacy and safety of acarbose (BAY g 5421) in the Rx of obese patients with NIDDM Rxed by diet alone [abstract]. Diabetes 1990; 39 (1 Suppl.): 211A
53. Donckier J, Williams G. The roles of α-glucosidase inhibitors in diabetes. Eur J Clin Invest 1994; 24 (3 Suppl.): 522-4
54. Splengler M, Hänsel G, Boehme K. Acarbose and Glibenclamid bei Typ II-Diabetes. Z Allgemeinmed 1990; 66: 606-10
55. Fölsch UR, Spengler M, Boehme K, et al. Efficay of glucosidase inhibitors compared to sulphonylureas in the treatment and metabolic control of diet treated type II diabetic subjects: two long-term comparative studies. Diabetes Nutr Metab 1990; 3 (1 Suppl.): 63-8
56. Pagano G, Cavallo-Perin P. Glucosidase inhibitors and biguanides in the treatment of non-insulin-dependent diabetic patients. Diabetes Nutr Metab 1990; 3(1 Suppl.): 69-76
57. Sachse G, Willms B. Effect of the α-glucosidase-inhibitor BAY g 5421 on blood glucose control of sulphonylurea-treated diabetics and insulin-treated diabetics. Diabetologia 1979; 17: 287-90
58. Sachse G, Mäser E, Laube H, et al. Effect of long-term acarbose therapy on the metabolic situation of sulfonylurea-treated diabetics. In: Creutzfeld W, editor. Proceedings of the First International Symposium on Acarbose; 1981 Oct 8-10: Montreux. Amsterdam: Excerpta Medica, 1982; 298-304
59. Willms B. Acarbose in non-insulin-dependent diabetes mellitus: combination with sulphonylureas and interaction with diet. In: Lefèbvre PJ, Standl E, editors. New aspects in diabetes. Berlin: De Gruyter, 1992: 165-76
60. Rosak C. Glucosidase inhibition and sulphonylurea secondary failure. Diab Nutr Metab 1990; 3 (1 Suppl.): 59-62
61. Raptis S, Dimitriadis G, Karaiskos C, et al. Short and long term studies of acarbose on various metabolic parameters and insulin requirements assessed by the artificial endocrine pancreas. In: Creutzfeld W, editor. Proceedings of the First International Symposium on Acarbose; 1981 Oct 8-10: Montreux. Amsterdam: Excerpta Medica, 1982: 393-401
62. Dimitriadis G, Karaiskos C, Raptis S. Effects of prolonged (6 months) α-glucosidase inhibition on blood glucose control and insulin requirements in patients with IDDM. Horm Metab Res 1986; 18: 253-5
63. Rybka J, Gregorová A, Zmydlená A, et al. Clinical study of acarbose. Drug Invest 1990; 2 (4 Suppl.): 264-7
64. Coniff F, Shapiro JA, Seaton TB, et al. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 1995; 18: 928-32
65. Sinay IR, Nusimovich B, Damilano S, et al. Acarbose; experimental assessment with the artificial pancreas. In: Creutzfeldt W, editor. Proceedings of the First International Symposium on Acarbose; 1981 Oct 8-10: Montreux. Amsterdam: Excerpta Medica, 1982: 461-70
66. Beyer JG, Schulz G, Jaeger H, et al. Improvement of carbohydrate tolerance in insulin dependent diabetics after administration of an α-glucosidase inhibitor demonstrated by the artificial pancreas. In: Creutzfeldt W, editor. Proceedings of the First International Symposium on Acarbose; 1981 Oct 8-10: Montreux. Amsterdam: Excerpta Medica 1982: 451-4
67. Rios MS. Acarbose and insulin therapy in type I diabetes mellitus. Eur J Clin Invest 1994; 24 (3 Suppl.): 36-39
68. Marena S, Tagliaferro V, Cavallero G, et al. Double-blind crossover study of acarbose in type 1 diabetic patients. Diabetic Med 1991; 8: 674-8
69. Schade DS. Prospective multicenter studies of the efficacy and safety of acarbose (Bay-g-5421) in the treatment of type I diabetes mellitus. In: Lefèbvre PJ, Standl E, editors. New aspects in diabetes mellitus. Berlin: De Gruyter, 1992: 237
70. Zavaroni I, Reaven GM. Inhibition of carbohydrate-induced hypertriglyceridemia by a disaccharidase inhibitor. Metabolism 1981; 30: 417-20
71. Vasselli JR, Haraczkiewicz E, Maggio CA, et al. Effects of aglucosidase inhibitor, acarbose (Bay-g-5421) on the development of obesity and fat motivated behaviour in Zucker (fafa) rats. Pharmacol Biochem Behav 1983; 19: 85-95
72. Yamashita K, Sugarawa S, Sakairi I, et al. Effects of an α-glucosidase inhibitor, acarbose, on blood glucose and serum lipids in streptozotocin-induced diabetic rats. Horm Metab Res 1984; 16: 179-82
73. Kritchevsky D, Tepper SA, Davidson LM, et al. Influence of acarbose (a glucosidase inhibitor) on experimental atherosclerosis in the rabbit. Artery 1990; 17: 170-5
74. Nestel PJ. Lower triglyceride production with carbohydrate-rich diet during treatment with acarbose. In: Creutzfeldt W, editor. Acarbose for the treatment of diabetes mellitus. Berlin: Springer-Verlag, 1988: 68
75. Clissold SP, Edwards C. Acarbose: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1988; 35: 214-43
76. Leonhard W, Hanefeld M, Fischer S, et al. Beneficial effects on serum lipids in non-insulin-dependent diabetics by acarbose treatment. Arzneimittelforschung 1991; 41: 735-8
77. Bishoff H. Pharmacology of a-glucosidase inhibition. Eur J Clin Invest 1994; 24 (3 Suppl.): 3-10
78. Thomas G, Keup U, Krause HP, et al. Pharmacological studies on acarbose. II: Antihyperlipaemic effects. In: Creutzfeldt W, editor. Proceedings of the First International Symposium on Acarbose; 1981 Oct 8-10; Montreux. Amsterdam: Excerpta Medica, 1982: 151-5
79. Raptis S, Dimitriadis G, Hdjidakis D. Acarbose treatment in insulin-dependent (type I) diabetes mellitus. In: Creutfeldt W, editor. Acarbose for the treatment of diabetes mellitus. New York: Springer, 1987: 141-52
80. Hillebrand I, Philipp E, Katsimantis D, et al. Acarbose (BAY g 5421), a possible treatment for patients with type IV hyperlipoproteinemia. In: Nestel PJ, editor. Proceedings of Poster Communications, 7th International Symposium on Atherosclerosis; 1985 Oct; Melbourne. Abstract no. 278
81. Walter-Sack IE, Wolfram G, Zöllner N. Effect of acarbose on serum lipoproteins in healthy individuals during prolonged administration of a fibre-free formula diet. Ann Nutr Metab 1989; 33: 100-7
82. Scheppach W, Fabian C, Sachs M, et al. The effect of starch ma absorption on fecal short-chain fatty acid excretion in man. Scand J Gastroenterol 1988; 23: 755-9
83. Gérard J, Lefèbvre PJ, Luyckx AS. Glibenclamide pharmacokinetics in acarbose-treated type 2 diabetics. Eur J Clin Pharmacol 1984; 27: 233-6
84. McCulloch DK, Kurtz AB, Tattersall RB. A new approach to the treatment of nocturnal hypoglycaemia using α-glucosidase inhibition. Diabetes Care 1983; 6: 483-7
85. Schrezenmeier J, Kasper H. Therapeutic effect of acarbose in reactive hypoglycaemia. In: Creutzfeldt W, editor. Proceedings of the First International Symposium on Acarbose; 1981 Oct 8-10: Montreux. Amsterdam: Excerpla Medica, 1982: 530
86. Gérard J, Luyckx AS, Lefèbvre PJ. Acarbose in reactive hypoglycaemia: a double-blind study. Int J Clin Pharmacol 1984; 22: 25-31
87. Richard JL, Rodier M, Monnier L, et al. Effect of acarbose on glucose and insulin response to sucrose load in reactive hypoglycaemia. Diab Metab (Paris) 1988; 14: 114-8
88. Buchanan KD, McLoughlin JC, Alam MJ. Acarbose in the dumping syndrome. In: Creutzfeldt W, editor. Proceedings of the First International Symposium on Acarbose; 1981 Oct 8-10. Montreux. Amsterdam: Excerpta Medica, 1982: 515
89. Speth PAJ, Jansen JBMJ, Lamers CBHW. Acarbose and pectin in the dumping syndrome. In: Creutzfeldt W, editor. Proceedings of the First International Symposium on Acarbose; 1981 Oct 8-10: Montreux. Amsterdam: Excerpta Medica, 1982: 524
90. Taylor RH, Jenkins DJA, Barker HM. Low-dose acarbose and the dumping syndrome. In: Creutzfeldt W, editor. Proceedings of the First International Symposium on Acarhose; 1981 Oct 8-10: Montreux. Amsterdam: Excerpta Medica, 1982: 527
91. Toeller M. Nutritional recommendations for diabetic patients and treatment with α-glucosidase inhibitors. Drugs 1992; 44 (3 Suppl.): 13-20
92. Bustamante S, Gasparo M, Kendall K, et al. Increased activity of rat intestinal lactase due to increased intake of α-saccharides (starch, sucrose) in isocaloric diets. J Nutr 1981; 111: 943-53
93. Yamada K, Bustamante S, Koldovsky O. Time- and dose - dependency of intestinal lactase activity in adult rats on starch intake. Biochem Biophys Acta 1981; 676: 108-12
94. Lee S, Bustamante S, Koldovsky O. The effect of alpha-glucosidase inhibition on intestinal disaccharidase activity in normal and diabetic mice. Metabolism 1983; 32: 793-9
95. Hillebrand I, Graefe KH, Bischoff H, et al. Serum digoxin and propranolol levels during acarbose treatment [abstract]. Diabetologia 1981; 21: 282-3
96. Gérard J, Lefèbvre PJ, Luyckx AS. Glibenclamide pharmacokinetics in acarbose-treated type 2 diabetics. Eur J Clin Phar macol 1984; 27; 233-6
97. Scheen AJ, Ferreira Alves de Magalhaes AC, Salvatore T, et al. Reduction of the acute bioavailability of metformin by the α-glucosidase inhibitor acarbose in normal man. Eur J Clin Invest 1994; 24 (3 Suppl.): 50-4
98. Peterson RG. α-Glucosidase inhibitors in diabetes: lessons from animal studies. Eur J Clin Invest 1994; 24 (3 Suppl.): 11-8
99. Lefèbvre PJ, Scheen AJ. The use of acarbose in the prevention and treatment of hypoglycaemia. Eur J Clin Invest 1994; 24 (3 Suppl.): 40-44